1. Mexico Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V.

LABB.MX
Genomma Lab Internacional, S.A.B. de C.V.MX flagMexican Stock Exchange
15.39
MXN
+0.06
- -
15.05BMarket Cap
Genomma Lab Internacional, S.A.B. de C.V.
LABB.MX
(Mexican Stock Exchange)

Recent

price

15.39

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.95
7.65
9.35
10.83
11.01
10.7
11.54
12.68
11.52
12.55
13.71
15.37
16.93
17.2
19.03
17.94
13.19
Revenue per Share
1.04
1.39
1.43
1.67
1.38
-1.04
-1.71
1.34
1.08
0.74
1.39
1.3
1.4
1.07
1.53
1.65
1.2
Basic EPS, GAAP
0.59
0.01
-0.17
-0.82
0.13
1.03
1.35
1.13
0.05
0.13
1.69
1.25
2.05
2
2.18
2.07
1.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.39
0.78
0.61
0.8
0.8
0.4
Dividend per Share
3.94
5.24
6.75
8.33
9.71
8.83
7.57
8.3
7.82
8.56
9.88
11.25
12.37
13.19
13.64
14.49
14.78
Book Value per Share
3.91
5.27
2.61
1.89
2.7
2.15
1.65
1.96
1.74
2.31
3.89
4.87
4.96
4.53
4.98
5.56
6.24
Tangible Book Value per Share
1,053
1,053
1,048
1,049
1,048
1,032
981
952
1,024
1,013
1,012
1,008
993
957
978
978
977
Basic Weighted Avg Shares
6,264
8,056
9,800
11,361
11,541
11,042
11,316
12,078
11,794
12,713
13,870
15,487
16,820
16,467
18,607
17,541
12,884
Sales/Revenue/Turnover
25.78
24.97
25.43
25.8
21.08
-0.62
1.68
20.69
18.54
17.89
21.15
19.35
19.64
19.44
20.99
21.41
21.26
Operating Margin (%)
79
82
66
64
98
118
84
70
81
142
159
170
227
227
360
379
278
Depreciation Expense
1,093
1,461
1,504
1,752
1,445
-1,069
-1,681
1,279
1,109
750
1,404
1,308
1,389
1,026
1,493
1,614
1,169
Net Income, GAAP
30.62
30.35
30.86
30.51
29.45
- -
- -
35.04
37.09
51.49
35.33
41.14
38.84
36.95
27.67
33.68
33.9
Effective Tax Rate (%)
17.45
18.14
15.35
15.43
12.52
-9.68
-14.85
10.59
9.41
5.9
10.12
8.44
8.26
6.23
8.02
9.2
9.08
Profit Margin (%)
3,136
4,443
5,586
6,833
9,542
5,043
2,696
1,536
4,512
4,139
5,424
4,950
1,956
3,997
5,528
5,699
6,009
Working Capital
- -
970
3,052
4,651
6,505
5,829
3,760
1,690
5,197
4,531
4,475
3,856
1,590
4,234
5,113
4,796
4,729
LT Debt
4,112
5,544
7,019
8,835
10,503
9,249
6,793
7,049
6,718
7,249
8,842
10,072
10,152
9,383
10,885
11,118
11,715
Total Equity
30.55
27.04
21.4
17.21
11.36
- -
- -
14.68
12.36
9.08
13.54
11.34
12.42
12.77
17.94
14.57
9.46
Return on Invested Capital (%)
39.84
27.83
18.49
15.27
10.35
- -
- -
11.15
10.93
7.29
10.89
9.29
9.5
8.24
11.04
10.29
7.15
Return on Capital (%)
38.36
30.26
23.89
22.17
15.28
-11.08
-20.33
16.68
13.94
8.99
15.04
12.26
11.76
8.24
11.5
11.74
8.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
2,832
3,329
LT Borrowings
- -
4,770
4,729
LT Finance Leases
- -
26
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
978
978
Market Capitalization
18,754
17,476
17,738

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
12,845
13,661
Cash, Cash Equivalents & STI
- -
3,054
2,809
Accounts Receivable, Net
- -
4,496
5,255
Inventories
- -
1,840
1,941
Total Current Liabilities
- -
7,145
7,652
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,832
3,329
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.77%
5.06%
2.14%
Free Cash Flow
131.61%
7.16%
-4.85%
Net Income, GAAP
-5.04%
5.37%
8.1%
Sales/Revenue/Turnover
4.92%
5.09%
-5.73%
Total Cash Common Dividend
- -
- -
0.38%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,197
4,651
5,093
4,666
18,607
2025
4,406
4,676
- -
4,017
17,541
2026
4,191
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
- -
0.7
-0.17
1.53
2025
0.51
0.36
- -
0.33
1.65
2026
0.51
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
- -
0.21
0.19
0.8
2025
0.2
- -
- -
0.2
0.8
2026
0.2
- -
- -
- -
- -
Similar Companies
Sonoma Pharmaceuticals, Inc. (SNOA)
Ionic Brands Corp. (IONKF)
Lotus Pharmaceutical Co., Ltd. (1795.TW)
Tristar Wellness Solutions Inc. (TWSI)
Applied Biosciences Corp. (APPB)
Guardion Health Sciences, Inc. (GHSI)
Business
Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX) develops, manufactures, markets and sells a broad portfolio of branded over-the-counter (OTC) pharmaceutical and personal care products primarily in Mexico, the United States and Latin America; core offerings include anti-acne treatments such as Asepxia, analgesics including Tafirol paracetamol and newly acquired IBU 400 ibuprofen, isotonic beverages like Suerox alongside Suero Repone and Suero Oral, gastro products such as Treg omeprazole, anti-flu remedies, antacids, anti-ulcer treatments, hemorrhoid and varicose vein therapies, ophthalmic medications, infant nutrition, dandruff shampoos, hair loss prevention products, muscle pain ointments, antifungal treatments, stress relief products, anti-wrinkle creams, soaps, razors and self-diagnosis kits, among over 50 brands distributed through more than 500,000 points of sale across 18 countries. The Mexico City-based company, founded in 1996, generates approximately 48% of net sales from Mexico, 42% from Latin America and 10% from the USA, with operations through subsidiaries in the United States, Peru, Chile, Ecuador and Honduras. In July 2024, Genomma Lab completed strategic bolt-on acquisitions of four brands—Suero Repone and Suero Oral in the USA to bolster its isotonic beverage presence in the Hispanic market, and IBU 400 and Treg in Argentina to expand into ibuprofen analgesics and strengthen gastro categories—for a total investment of US$25.6 million, leveraging local cash and debt; earlier in 2024, the company divested its stake in distributor Marzam, issued LAB 25 and LAB 25-2 unsecured bonds totaling MXN1.2 billion, announced multiple dividend payments and saw its pharma manufacturing facility receive pending GMP certification for the Mexican market.